ERBB2 and breast carcinoma: Turcotte et al36 showed that, in HER2+ breast cancer, NT5E expressed by tumor cells and host cells significantly suppresses the anti‐ErbB2‐mediated immune response, thereby promoting resistance to targeted therapy.